LeMaitre Vascular (LMAT) Stock Forecast, Price & News

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for LeMaitre Vascular in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" LMAT shares.
View LMAT analyst ratings or view top-rated stocks.

2 brokers have issued twelve-month target prices for LeMaitre Vascular's shares. Their LMAT share price forecasts range from $62.00 to $62.00. On average, they anticipate the company's stock price to reach $62.00 in the next twelve months. This suggests that the stock has a possible downside of 4.5%.
View analysts price targets for LMAT or view top-rated stocks among Wall Street analysts.

LeMaitre Vascular's stock was trading at $46.02 at the start of the year. Since then, LMAT shares have increased by 41.0% and is now trading at $64.91.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, July 27th 2023.
View our LMAT earnings forecast.

LeMaitre Vascular, Inc. (NASDAQ:LMAT) released its quarterly earnings data on Tuesday, May, 2nd. The medical instruments supplier reported $0.27 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.25 by $0.02. The medical instruments supplier had revenue of $47.08 million for the quarter, compared to analyst estimates of $43.54 million. LeMaitre Vascular had a net margin of 12.20% and a trailing twelve-month return on equity of 8.86%. The firm's revenue was up 19.0% compared to the same quarter last year. During the same quarter last year, the company earned $0.27 earnings per share.

LeMaitre Vascular announced a quarterly dividend on Monday, April 24th. Stockholders of record on Wednesday, May 17th will be given a dividend of $0.14 per share on Thursday, June 1st. This represents a $0.56 dividend on an annualized basis and a dividend yield of 0.86%. The ex-dividend date of this dividend is Tuesday, May 16th.
Read our dividend analysis for LMAT.

ETFs with the largest weight of LeMaitre Vascular (NASDAQ:LMAT) stock in their portfolio include ProShares Russell 2000 Dividend Growers ETF (SMDV), Invesco S&P SmallCap Health Care ETF (PSCH), SPDR S&P Health Care Equipment ETF (XHE), Hartford Multifactor Small Cap ETF (ROSC), Royce Quant Small-Cap Quality Value ETF (SQLV), Timothy Plan US Small Cap Core ETF (TPSC), iShares Micro-Cap ETF (IWC) and VictoryShares US Discovery Enhanced Volatility Wtd ETF (CSF).

LeMaitre Vascular (NASDAQ:LMAT) pays an annual dividend of $0.56 per share and currently has a dividend yield of 0.86%. The company has been increasing its dividend for 12 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio is 60.22%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, LMAT will have a dividend payout ratio of 38.62% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for LMAT.

LeMaitre Vascular updated its second quarter 2023 earnings guidance on Wednesday, May, 3rd. The company provided EPS guidance of $0.30-$0.35 for the period, compared to the consensus EPS estimate of $0.31. The company issued revenue guidance of $47.10 million-$49.50 million, compared to the consensus revenue estimate of $44.94 million.

13 employees have rated LeMaitre Vascular Chief Executive Officer George W. LeMaitre on Glassdoor.com. George W. LeMaitre has an approval rating of 33% among the company's employees. This puts George W. LeMaitre in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other LeMaitre Vascular investors own include AbbVie (ABBV), Sociedad Química y Minera de Chile (SQM), Gilead Sciences (GILD), Aurora Cannabis (ACB), Aurora Cannabis (ACBFF), NVIDIA (NVDA), Adobe (ADBE), Boeing (BA) and Salesforce (CRM).

LeMaitre Vascular trades on the NASDAQ under the ticker symbol "LMAT."

LeMaitre Vascular's stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (14.54%), Conestoga Capital Advisors LLC (8.37%), Copeland Capital Management LLC (6.18%), Ranger Investment Management L.P. (4.47%), State Street Corp (3.38%) and Dimensional Fund Advisors LP (3.00%). Insiders that own company stock include David B Roberts, George W Lemaitre, George W Lemaitre, John A Roush, Joseph P Pellegrino Jr, Lawrence J Jasinski and Trent G Kamke.
View institutional ownership trends.

Shares of LMAT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of LMAT stock can currently be purchased for approximately $64.91.

LeMaitre Vascular (NASDAQ:LMAT) has a market capitalization of $1.44 billion and generates $161.65 million in revenue each year. The medical instruments supplier earns $20.64 million in net income (profit) each year or $0.93 on an earnings per share basis.

The company employs 450 workers across the globe.

LeMaitre Vascular's mailing address is 63 SECOND AVENUE, BURLINGTON MA, 01803. The official website for the company is www.lemaitre.com. The medical instruments supplier can be reached via phone at (781) 221-2266 or via fax at 781-425-5049.